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Abstract 
This is the first randomised controlled trial to evaluate a protocol for cognitive 
behaviour therapy (CBT) for a Specific Phobia of Vomiting (SPOV) compared with a wait 
list and to use assessment scales that are specific for a SPOV. Method: 24 participants (23 
women and 1 man) were randomly allocated to either 12 sessions of CBT or a wait list. 
Results: At the end of the treatment, CBT was significantly more efficacious than the wait list 
with a large effect size (Cohen’s d = 1.53) on the Specific Phobia of Vomiting Inventory 
between the two groups after 12 sessions. Six (50%) of the participants receiving CBT 
achieved clinically significant change compared to 2 (16%) participants in the wait list group. 
Eight (58.3%) participants receiving CBT achieved reliable improvement compared to 2 
(16%) participants in the wait list group. Conclusions: A SPOV is a condition treatable by 
CBT but further developments are required to increase efficacy.    
 
Key words: emetophobia; specific phobia; vomiting; cognitive behaviour therapy; exposure; 
randomised controlled trial. 
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A Randomised Controlled Trial of Cognitive Behaviour Therapy or wait list for a Specific 
Phobia of Vomiting 
 
A specific phobia of vomiting (SPOV) (also known as “emetophobia”) is a neglected 
area of research. Its inclusion with Specific Phobia ‘Other type’ in the DSM may partly 
account for this (Boschen, 2007). A SPOV occurs predominantly in women and commonly 
develops in childhood with an average duration of 25 years before treatment (Lipsitz, Fyer, 
Paterniti, & Klein, 2001; Veale & Lambrou, 2006). Epidemiological studies suggest that the 
prevalence of specific phobias in general is extremely common with a 12-month prevalence 
of about 7–13% (Becker et al., 2007; Boyd et al., 1990; Kessler, Chiu, Demler, & Walters, 
2005; Stinson et al., 2007). Of these, only one study specifically enquired about a specific 
phobia of vomiting, which had a prevalence of 0.1% (Becker et al., 2007).  
Although a SPOV therefore appears relatively uncommon in the community 
compared with specific phobias in general (Becker et al., 2007), its prevalence may have 
been deflated in this study by misdiagnosis or comorbidity being given precedent  (Boschen, 
2007; Manassis & Kalman, 1990; Veale, 2009). For example, obsessive-compulsive 
symptoms may be observed in the compulsive washing or superstitious behaviours in SPOV 
that are performed in order to prevent vomiting (Veale, Hennig, & Gledhill, 2015). 
Hypochondriacal disorder may be misdiagnosed from the significant degree of worrying, 
reassurance seeking and checking behaviour about possible infections or food poisoning that 
could cause a person to vomit. Anorexia nervosa may be misdiagnosed when a person is 
underweight and restricting food to reduce the risk of vomiting. The person may have no 
disturbance in body image or in their self-evaluation, and may have no fear of gaining weight 
or becoming fat (Manassis & Kalman, 1990).   
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A SPOV therefore appears to be rare in the community from one study but this 
finding is partly at odds with a study that found that 8.8% of the community report a “fear of 
vomiting” (van Hout & Bouman, 2012). Clinicians report it is one of the more common 
specific phobias for treatment seeking. This could be because people with a SPOV are often 
significantly handicapped by the degree of their avoidance behaviour compared with other 
specific phobias (e.g. they may avoid a desired pregnancy, have a termination of pregnancy 
or avoid a surgical procedure (Veale & Lambrou, 2006). Lastly, the avoidance of certain 
types of food and disordered eating may cause the individual to become significantly 
underweight (Veale, Costa, Murphy, & Ellison, 2012)(Manassis & Kalman, 1990). A SPOV 
may manifest itself in three main ways: a fear of vomiting themselves, a fear of others 
vomiting (which may then lead to contagion and vomiting themselves) and a fear of vomiting 
in front of others and being evaluated negatively (Lipsitz et al., 2001; van Hout & Bouman, 
2012).  
To our knowledge, there has been no randomised controlled trial for treating a SPOV.  
A meta-analysis of randomised controlled trials that treated specific phobias in general found 
in-vivo exposure to have the most evidence (Wolitzky-Taylor, Horowitz, Powers, & Telch, 
2008). However, this review did not include any trials with a SPOV. It is not known whether 
a SPOV responds to exposure as well as other specific phobias or whether a protocol should 
include repeated exposure to actual vomiting. In addition, a generic protocol for exposure 
may at least need to be modified to include the repetitive (or “compulsive”) behaviours that 
can occur in emetophobia or to update early aversive memories of vomiting (Veale, Murphy 
et al, 2013). Most case reports in adults or children with SPOV treated by various forms of 
cognitive behaviour therapy that included exposure. There are potential practical problems 
with repeated exposure to oneself vomiting, and so most of the case reports have included 
various forms of graded exposure to cues of vomiting (Lesage & Lamontagne, 1985; Maack, 
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Deacon, & Zhao, 2013; McFadyen & Wyness, 1983). This has been supplemented by 
exposure to a video of others vomiting (Phillips, 1985), adding exposure to interoceptive cues 
(e.g. creating sensation of nausea) (Hunter & Antony, 2009), adding cognitive therapy and 
behavioural experiments that included exposure (Kobori, 2011), delivering CBT with 
exposure in a group format (Ahlen, Edberg, Di Schiena, & Bergström, 2015), adding 
cognitive restructuring and parent training to exposure (Graziano, Callueng, & Geffken, 
2010), adding a feeding program to exposure (Williams, Field, Riegel, & Paul, 2011), adding 
fluoxetine and clobazepam to exposure (Faye, Gawande, Tadke, Kirpekar, & Bhave, 2013), 
adding hypnotherapy to exposure (Wijesinghe, 1974) and lastly adding systemic behaviour 
therapy to exposure (O'Connor, 1983). Four case reports are described without exposure – 
one of imaginal coping (Moran & O’Brien, 2005), one of psychotherapy (Manassis & 
Kalman, 1990) and two reports of hypnotherapy including a form of imagery rescripting  
(McKenzie, 1994; Ritow, 1979). None of these single cases had an experimental design, and 
there is likely to be a publication bias of successful cases. Four of those reports involved 
atypical cases; for example, two of the reports were concerned predominantly with fear of 
others vomiting (McFadyen & Wyness, 1983; McKenzie, 1994) and two were of atypical 
social phobia or a preoccupation with nausea (Lesage & Lamontagne, 1985; McNally, 1997). 
None described a clear theoretical model of SPOV and only one recent study used a validated 
measure of a SPOV (Ahlen et al., 2015).  
Boschen (2007) first developed a model of a SPOV in which he suggested that people 
with SPOV may be more vulnerable to expressing anxiety through gastrointestinal somatic 
symptoms such as nausea and ‘‘butterflies’’, and these were misinterpreted as evidence of 
imminent vomiting. Veale (2009) emphasised the role of emotional conditioning in which 
vomiting has become associated with fear and disgust. Past aversive experiences of vomiting 
(and their cues) become fused with the present often through imagery (Price, Veale, & 
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Brewin, 2012; Veale, Murphy, Ellison, Kanakam, & Costa, 2013) so that the memories are 
re-experienced as if they are about to be repeated. Once the association is learned, the core 
catastrophic appraisal is of nausea as impending vomit and loss of control and the evaluation 
of vomiting as one of extreme awfulness leading to further anxiety and disgust. There are 
various responses that then maintain the fear including: (a) experiential avoidance of thoughts 
and images of the self or others vomiting and interoceptive cues for nausea, (b) avoidance of 
external cues that could lead to vomiting; (c) hyper-vigilance for monitoring external threats; 
(d) self-focussed attention and hyper-vigilance for nausea and other gastro-intestinal 
sensations; (e) worry, self-reassurance and mental planning of escape routes from others 
vomiting; (f) magical thinking and neutralizing to stop oneself from vomiting; (g) safety-
seeking behaviours, including compulsive checking and reassurance seeking (Veale, Hennig, 
et al., 2015).  
A treatment protocol of CBT (Veale, 2009) based on this model includes psycho-
education, a formulation of cognitive processes and behaviours maintaining the fear, imagery 
re-scripting of past aversive experiences of vomiting (Holmes, Arntz, & Smucker, 2007; 
Veale, Page, Woodward, & Salkovskis, 2015), exposure in vivo to cues of vomiting, exposure 
in imagination and role-plays of vomiting, as well as the dropping of safety-seeking and 
compulsive behaviours. This model and protocol has not been previously evaluated. Our aim 
in this RCT was to determine if CBT with this protocol is more clinically effective than a 
wait list with specific outcome measures for SPOV.  
Method 
The results are reported according to the CONSORT checklist.  
Trial design 
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 A randomised controlled trial in which participants were allocated to either cognitive 
behaviour therapy or a wait list in equal ratio. There were no changes to the design after the 
trial commenced.  
Participants 
The eligibility criterion for participation was the diagnosis of SPOV, using the 
Structured Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & Williams, 1995). 
Additional inclusion criteria were as follows: (a) the diagnosis of SPOV must be regarded by 
the clinician and participant as their principle diagnosis, (b) aged 18 or above; (c) on stable 
psychotropic medication for 12 weeks prior to randomisation (if relevant); (d) no plans to 
commence or increase the dose of any psychotropic medication; (e) willingness/ability to 
travel to the clinic weekly; and (f) a total score of at least 15 on the Specific Phobia of 
Vomiting Inventory (Veale, Ellison, et al., 2013). Exclusion criteria were as follows: (a) 
those with an exclusive a fear of others vomiting (not of self) as this is atypical; (b) those 
with a diagnosis of schizophrenia or other psychotic disorder, alcohol or substance 
dependence, domestic violence, other violent or self-destructive behaviours, or other issue 
that required treatment in its own right or may interfere in the delivery of therapy; (c) those 
with suicidal or homicidal intent; (d) those whose English was not sufficiently fluent for 
CBT; (e) those currently receiving another form of psychotherapy; (f) those who had received 
CBT for SPOV within the past 6 months.    
 Participants were provided with a rationale and description of the treatment during the 
initial phone screening and intake session with the principal investigator. The setting for the 
study was outpatient private-practice office locations in San Diego County, which included 
one in La Mesa (n = 4), one in Carlsbad (n = 4), and one in Escondido (n = 4) for the CBT 
group. All three therapists were doctoral level and licensed.  One therapist had minimal 
experience with emetophobia and exposure therapy. The other two had no experience with 
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emetophobia.  All three therapists were experienced in CBT. Only one therapist participated 
at each practice site. The principal researcher provided detailed instructions both face to face 
and in written form; and supervised the therapists via audio recording. The principal 
investigator was available 24/7 to provide support or answer questions. The treatment was 
provided at no charge. The study was approved by the Institutional Review Board of Argosy 
University Southern California. 
Interventions 
Treatment used a CBT protocol of 12 sessions of approximately 60 minutes duration. 
The therapists were supervised in the delivery of the therapy throughout the study. Phase 1 
(sessions 1-3) of treatment included assessment by the clinician and an agreed-upon 
formulation of the maintenance of fear. Goal-setting emphasized an improved quality of life 
and commitment to the values of each participant. Psycho-education about vomiting as 
normal and adaptive was provided along with information about the experience of anxiety 
and disgust as they relate to a SPOV. It included an assessment of safety seeking and 
avoidance behaviors in maintaining symptoms. The importance of practice between sessions 
was emphasised with the dropping of safety seeking behaviours as a first step.  
Phase 2 (session 3-5) of treatment addressed the presence of flash-forwards and 
flashbacks related to traumatic memories of self or others vomiting.  Flash-forwards were 
addressed using imaginal exposure. Flashback memories were addressed with a trauma 
model using imagery rescripting.  
Phase 3 (sessions 4-7) focussed on dropping the safety-seeking behaviors and 
cognitive processes contributing to fear. These include an overinflated belief in the ability to 
control vomiting or events that might lead to vomiting, the need for certainty and control over 
thoughts and feelings about vomiting, attentional biases and meta-cognitions about worry that 
have the unintended consequences of increasing anxiety. Exploring and testing beliefs about 
Running head: CBT for SPOV  9 
gastrointestinal sensations and any related misappraisal addressed the cognitive processes 
contributing to fear. Arousal-management skills were taught by decreasing self-focussed 
attention to nausea or other somatic sensations and mindful acceptance of the internal 
experience. The unintended consequences of safety-seeking behaviours such as mental 
planning, self-reassurance, and vigilance were highlighted in the way they increase 
preoccupation, distress and interference in life.  
Phase 4 (sessions 6-12) of treatment included a presentation of the rationale for 
graded exposure to both internal and external cues for vomiting. A hierarchy of feared 
situations or activities (including avoided foods) was created. Homework and in-session 
intervention included exposure in vivo to items on the hierarchy and other cues of vomiting, 
such as pictures, sounds or smells of vomit, exposure in imagination of vomiting and role-
playing of past experiences of vomiting. Interoceptive exposure (i.e. eating until full, 
spinning, reading in the car) was used if appropriate. Exposure to the participant actually 
vomiting was not used. This was because (a) clinical experience suggests that when people  
with a SPOV have had exposure to self-induced vomiting, they have reported that it made 
them even more determined never to vomit, (b) there are no single case experimental designs 
with long term outcomes described for exposure to actual vomiting that can guide a clinician. 
Although a behavioural experiment of one episode of vomiting might theoretically assist in 
altering expectations (especially in someone who cannot recall vomiting in their life), 
vomiting is difficult to repeat for increasing tolerance. Repeated self-induced vomiting may 
also be associated with electrolyte imbalance or damage to the dental enamel.  
Finally, psychoeducation on relapse prevention (sessions 12) was provided so 
participants understood that gains are maintained through regular exposure to feared 
situations.  
Outcomes 
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Outcome measures were administered at assessment, at mid-treatment, at end of 
treatment, and at follow up. Post-treatment measures were collected after the end of the 12th 
session or after 12 weeks on the wait list. The follow-up measures were collected between 1.5 
and 2 months after the end of treatment and usually returned via the postal system. The 
primary outcome measure was the Specific Phobia of Vomiting Inventory (SPOVI) (Veale, 
Ellison, et al., 2013). This is a self-report measure that consists of 14 items rated for 
frequency ranging from 0 (not at all) to 4 (all the time). The total score ranges from 0 to 56. 
The scale has a two-factor structure, with one factor of 7 items characterized by avoidance 
(e.g. “I have been trying to avoid or control any thoughts or images about vomiting”) and a 
second factor of 7 items comprised of threat monitoring (e.g. “I have been focused on 
whether I feel ill and could vomit rather than on my surroundings”). Cronbach’s α was .91. 
The secondary outcome measures were:  
1) Emetophobia Questionnaire (EmetQ) (Boschen, Veale, Ellison, & Reddell, 2013). 
The EmetQ is a 13-item scale and the range is 13-65. The EmetQ has 3 factors. Factor 1 had 
6 items focused on avoidance of travel, movement, or locations. Factor II was comprised of 3 
items, which centered on themes of dangerousness of exposure to vomit stimuli. Factor III 
consisted of 4 items that were focused on avoidance of others who may vomit. Cronbach’s α 
was 0.82.  
2) Health Anxiety Inventory (HAI) (Salkovskis, Rimes, Warwick, & Clark, 2002). 
The HAI is an 18-item self-rated measure of health anxiety. The range for the total is 0-42. 
Cronbach’s α was .95. The HAI was included because people with SPOV often score highly 
on this scale (Veale, Ellison et al, 2013).  
3) The Anxiety Sensitivity Inventory (ASI) (Reiss, Peterson, Gursky, & McNally, 
1986; Vujanovic, Arrindell, Bernstein, Norton, & Zvolensky, 2007). The ASI is a 16-item 
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scale that measures sensitivity to anxiety symptoms. The range of the total score is from 0 to 
64 and Cronbach’s α was 0.83.  
4) Patient Health Questionnaire (PHQ-9) (Kroenke, Spitzer, & Williams, 2001). The 
PHQ-9 is a 9-item measure of depressive symptoms, based on DSM-IV. The total score 
ranges from 0 to 27 and Cronbach’s α was .86. A measure of depression was included as 
there is often comorbidity or depressive symptoms.  
5) The Sheehan Disability Scale (SDS) (Sheehan, Harnett-Sheehan, & Raj, 1996). 
This is a 5-item scale that measures degree of impairment and has a range of 0 (unimpaired) 
to 30 (highly impaired). Cronbach’s α was 0.89.  
Sample Size 
The sample size was calculated on the following assumptions from routine audit. If 
the SPOVI score is 16 after CBT and 35 on the wait list with a pooled standard deviation of 
15 and alpha (type 1 error) of 0.05 and power of 0.80, then the sample size required is 10 per 
group. Assuming two drop-outs per group, this would require 12 per group to be recruited or 
a total of 24. There was no clustering by care providers.  
Randomisation 
Participants were randomly assigned to either the treatment condition or the control 
condition, by the use of a predetermined randomised sequence list created by Microsoft 
Office Excel 2007. The participants assigned to the CBT group were assigned to a clinician 
based on location and convenience of travel.  
The random allocation sequence was concealed in a locked file until interventions were 
assigned. 
The principal investigator generated the allocation sequence, enrolled participants, and 
assigned participants to their groups after randomisation. 
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Blinding. Participants or those administering the interventions were not blinded to group 
assignment.  
Statistical Methods 
Factorial ANOVA was used to determine change for emetophobic symptoms and 
other general measures across time. Repeated measures ANOVA was used in which time was 
measured at 3 points across 2 groups. The effect size was calculated using Cohen’s d and Eta 
Squared (n2). Using Cohen’s d, > 0.8 is regarded as a strong effect size, while > 0.5 and 0.2 
are moderate and weak effect sizes respectively. Using n2, a strong effect size is > 0.14, while 
moderate and weak effect sizes are > 0.06 and 0.01 respectively. The numbers in each group 
who achieved reliable and clinically significant change was determined on the SPOVI and 
EmetQ at follow-up (Jacobson & Truax, 1991). We used criterion ‘c’, which is the greater 
likelihood of a participant being in the normative distribution than a clinical distribution after 
treatment. Criterion ‘c’ for the SPOVI was a cut-off score of 8 calculated from a clinical 
group (mean 30.6, SD 12.9) and a community group (mean 1.5, SD 3.5) and the repeat 
reliability from a clinical sample (r = 0.85) in a previous study (Veale et al., 2012). For the 
EmetQ, criterion ‘c’ was a cut-off score of 23 calculated from a clinical group (mean 37.25, 
SD 8.91) and a community group (mean 10.58, SD 7.63) and the repeat reliability from a 
clinical sample (r = 0.76) (Boschen et al., 2013).   
Results 
Participant flow 
Figure 1 is a CONSORT flow diagram of the progress during different phases. There 
were no protocol deviations from the study as planned.  
 ---------------------------------Figure 1 about here----------------------------------  
Implementation of intervention 
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Participants in the CBT group took 12 to a maximum of 23 weeks (n = 1). The mean 
was 18 weeks to complete the 12 sessions due to illness, vacations or other events. All 
participants in the wait list group completed their measures at 12 to 20 weeks with a mean of 
13 weeks.   
Recruitment 
Participants were recruited between May 2013 and June 2014, and followed up 
between approximately 1.5 and 2 months after completion of treatment.   
Baseline data 
The baseline demographic and clinical characteristics of each group are provided in 
Table 1. Three in the CBT group were taking one or more psychotropic medications 
(clonazepam, alprazolam, 2 on escitalopram, aripiprazole, olanzapine), as were five in the 
wait list group (lorazepam; bupropion; sertraline; quetiapine; and two on alprazolam). Four in 
the CBT group had had one or more previous psychological therapies for SPOV (two CBT 
without exposure and two psychotherapy); six in the wait list group had had previous therapy 
(four CBT without exposure; four hypnotherapy; three psychotherapy; and one EMDR).  
Numbers analysed 
Analysis was by “intention-to-treat”. In the CBT group, one participant dropped out 
and had missing data at the end of treatment and so their mid-treatment data were carried 
forward. In the wait list group, none had missing data at the end of treatment.  
There were two participants in the CBT group with missing data at follow-up. These 
were excluded as there was a possibility of deterioration or relapse. After the wait list, 
participants were offered CBT and a further seven were treated and included in a within 
group analysis. Three declined further treatment after the waiting list and two had medical 
reasons to prevent treatment at this time.  
Outcomes and estimation 
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The therapist completed a checklist of interventions used after each session. Each 
treatment session was audiotaped to ensure fidelity to the protocol; over 13% of random 
session recordings were audited by the first named author. Client value focussed goal-setting, 
psycho-education, addressing safety behaviours, weekly homework, arousal management, 
addressing cognitive processes, exposure, and relapse prevention were part of treatment for 
every group participant. Other strategies included on the checklist were used as needed. 
There was only one deviation from the protocol in the sessions that were audited. In this case 
the therapist was immediately retrained in the procedure of Imagery Rescripting before 
resuming sessions.   
The primary outcome measure and estimated effect size on each of the main outcome 
measures are shown in Table 2. There were no significant differences between groups pre-
treatment on any of the measures. Repeated measures ANOVAs were conducted for each of 
the primary and secondary outcome measures. For the primary outcome, the SPOVI, post-hoc 
pairwise comparisons found that SPOVI scores were significantly lower in the CBT group 
than the control group at mid-treatment (p < .01) and post-treatment (p ≤ .001). In addition, 
within the CBT group, SPOVI scores were significantly lower at mid-treatment compared to 
pre-treatment (p ≤ .001), and at post-treatment compared to pre-treatment (p ≤ .001). There 
was no significant difference in outcomes between the therapists at the three centres. 
Analysis is however limited by the small numbers.   
A similar pattern of results was seen for EmetQ scores, the significant interaction was 
between the groups at mid-treatment (p < .05) and post-treatment (p ≤ .001), with the CBT   
group having lower scores than the wait-list group. Similarly, within the CBT group EmetQ 
scores were significantly lower at mid-treatment compared to pre-treatment (p ≤ .001), and at 
post-treatment compared to pre-treatment (p ≤ .001).  
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In regards to HAI scores, post-hoc pairwise comparisons revealed that there was no 
significant difference between wait list and CBT group scores at any time. The HAI scores 
were significantly lower at post-treatment than mid-treatment in the wait list group (p < .05). 
Within the CBT group, the HAI was significantly lower between post-treatment and pre-
treatment (p ≤ .001) in the CBT group (p < .01).  
A significant main effect of time but not group was found for ASI scores, and post 
hoc pairwise comparisons revealed the only significant differences between wait list and CBT 
groups was at post-treatment (p < .01). There was no significant difference between any time 
points for the wait list group. ASI scores were significantly lower within the CBT group at 
mid-treatment compared to pre-treatment (p < .01), at post-treatment compared to mid-
treatment (p < .05).  
For PHQ-9 scores there was a significant effect of time, with post hoc pairwise 
comparisons showing that the significance was between pre and post-treatment (p ≤ .05), 
with post-treatment PHQ-9 scores being significantly lower than pre- and mid-treatment 
scores. However, there was no effect of group or any interaction.  
For the Sheehan Disability Scale, post hoc pairwise comparisons revealed that there 
was a significant difference between SDS scores of wait list and CBT at mid-treatment (p < 
.05) and post-treatment (p < .05). There was a significant reduction in SDS scores within the 
CBT group for pre to post-treatment (p ≤ .001).  
There was a very large effect size (d = 1.53) between the groups with a confidence 
interval of 0.62 - 2.44, for the primary outcome measure between the two groups after 12 
sessions (Table 2). Information on secondary outcomes is also presented in Table 2.  Table 3 
provides the categorical outcomes on reliable and clinically significant change. Here the 
SPOVI was more sensitive to change than the EmetQ with half of the participants achieving 
clinically significant change on the SPOVI compared to a quarter on the EmetQ. Eight out of 
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12 participants made reliable improvement on the SPOVI in CBT compared to two out of 12 
in the wait list. Numbers who showed reliable improvement on the SPOV were compared for 
the CBT and wait list group, with Fisher’s exact probability test revealing that significantly 
more participants in the CBT group achieved reliable improvement compared to those in the 
wait list group as measured by the SPOV (p ≤ .05) and the EmetQ (p ≤  .05).  
Participants on the waiting list were offered CBT (n=7) at the end of the trial and their 
outcome data is provided in Supplementary Table 4 and 5. The effect size on the SPOVI in 
the group receiving CBT after the wait list was similar to that found in the first group (d = 
1.96) and the proportion of participants who achieved clinically significant change and 
reliable improvement was also similar to the first group at follow-up.  
Adverse events 
There were no reported adverse events from treatment.   
Discussion 
This is the first randomised controlled trial of individual CBT delivered by a therapist 
for SPOV, which demonstrated that CBT is superior to a waiting list on rating scales, which 
are specific for a SPOV. There was a large effect size in the main outcome measure, with 
significantly lower scores by the end of treatment for patients in the CBT group compared to 
those in the wait list group, and by the end of treatment 50% achieved reliable and significant 
change. Treatment gains were maintained at follow-up. The most common outcome was of 
reliable improvement suggesting that nearly 2/3 of participants can expect as a minimum a 
change from a phobia to a fear of vomiting and to be significantly less distressed and more 
functional in their life. This might be a similar state to the 8.8% of the community who report 
a fear of vomiting who have mild distress or interference in life but do not have a diagnosis 
of a SPOV (van Hout & Bouman, 2012). The treatment was acceptable in the CBT group 
with only one dropout. Change was demonstrated in two specific measures for a SPOV as 
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well as general measures of psychopathology and disability. The study has highlighted 
greater sensitivity to change in the SPOVI than the EmetQ. This may be because the SPOVI 
includes several cognitive processes and safety behaviours, whereas the EmetQ is weighted 
more towards behavioural avoidance. The frequency of cognitive processes may therefore 
decrease before behavioural avoidance. There are no RCTs to compare with, although one 
report of group CBT found a within group effect size on the EmetQ of Cohen’s d of 1.18 at 3 
months (Ahlen et al., 2015).   
The main limitation of the study is the small sample size. Therefore, there was a wide 
confidence interval in effect size. Further limitations are that there was no clustering by care 
providers although there were no differences in therapist treatment effect, which would be 
difficult to obtain with such small numbers. The comparator was a waiting list and it is not 
therefore possible to determine the degree of therapist non-specific effects. Further research 
is required to compare CBT against a treatment, which is rated by participants as having 
equal credibility and expectation for change. Intention to Treat Analysis was justified since 
missing data occurred only in the CBT group, which may bias the outcome against the 
treatment group. Outcomes were at 1-2 month follow-up and it is not known whether 
improvements were maintained in the long term. The outcome was dependent on self-report 
and there was no blind observer (for example, a behavioural avoidance measure of vomiting 
or a repeat of the structured clinical interview for a diagnosis of a specific phobia). Two 
participants made reliable improvement on the SPOVI (of whom one made improvement on 
the EmetQ) whilst on the wait list. Given the chronic nature of a SPOV, this is unusual. On 
further enquiry, these two participants were atypical in their presentation. The first 
participant's symptoms were mainly present before and during travelling, which she did quite 
often and necessitated some accommodation of her schedule in order to participate in the 
study (i.e. measures were completed when she was not travelling); the other participant 
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qualified for the study with a minimum score, had little avoidance, no concerns with food, 
and few safety behaviours. Her main distress was when her husband was sick and she was 
also avoiding pregnancy due to her fear. The first went on to complete the treatment 
component of the study and reported it was still helpful for her. The second participant 
dropped out before the treatment component. Excluding milder or episodic variations of 
SPOV may be an important in future RCTs.   
Generalizability 
Because very little is published on a specific phobia of vomiting, it is not known how 
representative our sample is. We excluded people who exclusively fear others vomiting rather 
than their selves vomiting and therefore the results cannot be generalised to this population.          
The phobia was judged to be the principle diagnosis and there was limited comorbidity. The 
exclusion criteria were standard for RCTs in CBT and there were no exclusions because of 
the criteria. To date, this trial is the best available evidence for the treatment of a SPOV by 
CBT with a RCT. The participants were self-referred and recruited by advertising but there is 
no evidence that they are different to patients presenting in routine clinics. It should be 
possible to generalise the treatment protocol to routine clinic patients.    
Overall Evidence 
Our conclusion is that a SPOV is a treatable condition but not everyone responds. In 
such cases, the treatment may need to be stepped up to a more intensive programme (e.g. a 
longer treatment with more therapy assisted exposure similar to stepped care in obsessive 
compulsive disorder (Veale et al., 2016). Further research is required to improve outcome 
and to evaluate a time-intensive CBT similar to treating other specific phobias (Davis III, 
Ollendick, & Öst, 2012).  
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Figure 1. 
Flowchart for participants 
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Table 1. 
Characteristics of Participants by CBT and Wait List Group 
Variable  
CBT (n = 
12) 
Wait List (n = 
12) 
t df p d 
 
Age in Years, M (SD) 
 35 (8) 32 (17) -0.48 22 0.64 0.23 
Age at Onset, M (SD)  5 (4) 6 (3) 0.51 22 0.10 0.28 
  
CBT (n = 
12) 
Wait List (n = 
12) 
X2 df p V 
Gender Male 1 0 1.77 1 0.18 0.38 
 Female 11 12 
No. of Children  11 7 1.84 2 0.56 0.20 
Marital Status Married 10 7     
 Never Married 2 4 2.20 2 0.37 0.21 
 Widowed 0 1     
        
Ethnicity Caucasian 7 9     
 Hispanic 4 3 0.35 1 0.67 0.12 
 Unstated 1 0     
        
Comorbid current Diag. Depressive Disorder 2 1     
 GAD 0 1     
 OCD 0 1     
 Other phobia  0 1     
 Panic Disorder 1 3     
           With agoraphobia 1 1     
 Social Phobia   1 0     
 Anxiety Disorder NOS 1 0     
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Table 2. 
Mean, standard deviation, probability and effect sizes within and between groups  
  
Cognitive Behaviour Therapy 
(n = 12) 
Waiting List 
(n = 12) 
Comparisons of Main 
Effects and Interactions 
1. Time 
2. Intervention 
3. Time x Intervention 
Between Group 
Differences 
Measure Time Mean (SD) 
ES (Cohen’s d) 
[95% CI] 
Mean (SD) 
ES (Cohen’s d) 
[95% CI] 
F(df) = F value (p),  
ES (n2) [90% CI] 
ES (Cohen’s d) 
[95% CI] 
p 
Specific 
Phobia of 
Vomiting 
Inventory 
Pre- 28.75 (12.47)  32.92 (12.07)  1. F(1.38, 30.44) = 11.72 c 
n2 = 0.35 [0.12, 0.51] 
  
Mid-  14.33 (10.47)  32.67 (16.79)  2. F(1, 22) = 9.20 b 
n2 = 0.30 [0.09, 0.54] 
1.31 [0.43, 2.19] b 
Post-  9.50 (9.02) b 1.77 [0.83, 2.71] 30.75 (17.44)  3. F(1.38, 30.44) = 8.16 b 
n2 = 0.27 [0.06, 0.44] 
1.53 [0.62, 2.44] c 
Follow-up 6.20 (6.63) b 2.26 [1.23, 3.28] 
 
     
Emetophobia 
Questionnaire 
Pre- 48.33 (8.33)  52.67 (6.80)  1. F(2, 44) = 12.46 c 
n2 = 0.36 [0.16, 0.49] 
  
Mid-  40.50 (11.62)  50.83 (10.46)  2. F(1, 22) = 7.87 b 
n2 = 0.26 [0.04, 0.46] 
1.19 [-0.26, 2.13] a 
Post-  35.17 (12.42) 
b 
1.24 [0.37, 2.12] 51.67 (8.98)  3. F(2, 44) = 8.80 c 
n2 = 0.29 [0.09, 0.42] 
1.52 [0.61, 2.43] c 
Follow-up 28.90 (11.37) 
b 
1.95 [0.98, 2.92] 
 
     
Health Anxiety 
Inventory  
Pre- 22.50 (11.21)  21.17 (9.06)  1. F(2, 44) = 11.31 c 
n2 = 0.34 [0.14, 0.47] 
  
Mid-  18.33 (7.57)  22.25 (10.52)  2. F(1, 22) = 0.33 
n2 = 0.02 [0.00, 0.17] 
  
Post-  15.00 (6.86) a 0.81 [-0.03, 
1.64] 
18.50 (9.08) b 0.38 [-0.43, 
1.19] 
3. F(2, 44) = 3.54 a 
n2 = 0.14 [0.00, 0.27] 
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ES, Effect size, SD, standard deviation; a = p < 0.05; b=p < 0.01; c = p ≤ 0.001, compared to pre-treatment or between groups 
 
Follow-up 15.25 (7.96) b 0.75 [-0.08, 
1.57] 
 
   
 
 
 
  
 
Anxiety 
Sensitivity  
Index  
 
Pre- 
 
28.42 (13.04) 
  
 29.58 (7.56) 
 
 1. F(2, 44) = 7.22 b 
n2 = 0.25 [0.06, 0.39] 
  
Mid-  20.33 (10.47) 
b 
0.68 [-0.14, 
1.51] 
27.25 (11.38)  2. F(1, 22) = 3.51 
n2 = 0.14 [0.00, 0.35] 
  
Post- 15.75 (10.28) 
c 
1.08 [0.22, 1.94] 29.42 (11.03)  3. F(2, 44) = 6.08 b 
n2 = 0.22 [0.04, 0.36] 
1.28 [0.40, 2.16] b 
Follow-up 13.25 (9.77) c 1.32 [0.43, 2.20] 
 
     
Patient Health 
Questionnaire  
Pre- 6.50 (6.33)  5.92 (5.89)  1. F(2, 44) = 4.87 a 
n2 = 0.18 [0.02, 0.32] 
  
Mid-  5.25 (5.21)  7.92 (5.89)  2. F(1, 22) = 0.86 
n2 = 0.04 [0.00, 0.22] 
  
Post-  2.58 (2.69)  5.67 (3.89)  3. F(2, 44) = 2.80  
n2 = 0.11 [0.00, 0.24] 
0.92 [0.08, 1.77] a 
Follow-up 2.92 (2.75)       
        
Sheehan 
Disability  
Scale 
Pre-  13.58 (8.23)  11.83 (7.63)  1. F(1.55, 34.15) = 8.47 b 
n2 = 0.28 [0.07, 0.44] 
  
Mid- 6.33 (7.04) b 0.95 [0.10, 1.79]   14.33 
(10.17) 
 2. F(1, 22) = 2.41  
n2 = 0.10 [0.00, 0.30] 
  
Post- 3.83 (6.77) c 1.29 [0.41, 2.17] 12.08 (9.37)  3. F(1.55, 34.15) = 12.21 c 
n2 = 0.36 [0.13, 0.51] 
0.97 [-4.25, 2.30] a 
Follow-up 3.92 (6.78) c 1.28 [0.40, 2.16] 
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Table 3.  
Numbers who made clinically significant change and reliable improvement in CBT and Wait List Group  
 
 
 
 
 
 
 
 
 
 
 
 
  
Clinically significant 
change 
Reliable improvement  
No reliable 
change 
Reliable deterioration 
 
CBT (n = 12) 
 
SPOVI 
 
6 (50%) 
 
8 (66.7%) 
  
4 (33.3%) 
 
0 
Emet-Q 3 (25%) 6 (50%)  6 (50%) 0 
Wait List (n = 12) SPOVI 2 (16.7%) 2 (16.7%)  10 (83.3%) 0 
Emet-Q 0 (0%) 1 (8.3%)  11 (91.7%) 0 
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Supplementary Table 4. 
Numbers who made clinically significant change and reliable improvement at follow-up in those who received CBT after wait list 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinically significant 
change 
Reliable improvement  
No reliable 
change 
Reliable deterioration 
SPOVI (n= 7) 3 (42.8%) 4 (57.1%)  3 (42.8%) 0 
EmetQ (n= 7) 1 (14.2%) 6 (85.7%)  1 (12.5%) 0 
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Supplementary Table 5.  
Post-treatment and follow-up of mean, standard deviations and effect sizes for group who received CBT after the wait list (n=7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ES, 
effect size; SD, standard deviation; CI, confidence interval. * p < 0.05; ** p < 0.01; *** p ≤ 0.001, compared to pre-treatment 
  
Measure Time Mean (SD) p 
ES; Cohen’s d 
(95% CI) 
Specific Phobia of Vomiting Inventory Pre-Treatment 29.29 (12.58)   
Mid-Treatment 15.14 (9.13)  1.21 [-4.55, 6.96] 
Post-Treatment 8.00 (7.03) ** 1.96 [-3.38, 7.29] 
Follow-up 8.29 (6.65) **        1.95 [-3.32, 7.22] 
Emetophobia Questionnaire Pre-Treatment 50.86 (7.56)   
Mid-Treatment 38.29 (8.61) ** 1.45 [-2.79, 5.70] 
Post-Treatment 29.86 (10.21) *** 2.19 [-2.52, 6.89] 
Follow-up 30.71 (11.40) *** 1.95 [-3.12, 7.02] 
Health Anxiety Index  Pre-Treatment 18.57 (10.35)   
Mid-Treatment 14.43 (8.44)  0.41 [-4.54, 5.36] 
Post-Treatment 11.43 (6.77)  0.76 [-3.82, 5.35] 
Follow-up 12.14 (8.23) * 0.64 [-4.25, 5.54] 
Anxiety Sensitivity Index 
 
Pre-Treatment 28.29 (11.86)   
Mid-Treatment 15.57 (11.18) ** 1.03 [-5.00, 7.07] 
Post-Treatment 13.29 (10.66) ** 1.25 [-4.66, 7.15] 
Follow-up 9.29 (8.93) *** 1.69 [-3.81, 7.19] 
Patient Health Questionnaire Pre-Treatment 5.25 (8.49)   
Mid-Treatment 7.25 (7.12)  -0.24 [-4.34, 3.87] 
Post-Treatment 3.75 (3.41)  0.22 [-3.17, 3.61] 
Follow-up 2.75 (3.36)  0.36 [-3.02, 3.74] 
Sheehan Disability Scale Pre-Treatment 10.00 (6.58)   
Mid-Treatment 7.71 (6.10)  0.34 [-2.99, 3.66] 
Post-Treatment 5.71 (4.87)  0.69 [-2.34, 3.73] 
Follow-up 3.58 (4.53) * 1.06 [-1.90, 4.02] 
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